Description
AF-353 is a noncompetitive dual antagonist of the purinoreceptors P2X
3 and P2X
2/3 (IC
50s = 10 and 79.4 nM, respectively). It is selective for P2X
3 and P2X
2/3 over P2X
1, P2X
2, P2X
4, P2X
5, and P2X
7 (IC
50 = >10 μM for all). It inhibits calcium flux in CHO-K1 cells expressing the rat P2X
3 receptor and in 1321N1 cells expressing the human P2X
3 and P2X
2/3 receptors (IC
50s = 8.91, 8.71, and 38.9 nM, respectively). AF-353 decreases the electrical signals in the detrusor, but not striated, muscle of the bladder in female rats.
Uses
AF-353 (Ro-4) is a potent, selective and orally bioavailable P2X3/P2X2/3 receptor antagonist, with a pIC50 of 8.0 for both human and rat P2X3, and with a pIC50 of 7.3 for human P2X2/3[1][2].
References
[1] Gever JR, et al. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol. 2010 Jul;160(6):1387-1398. DOI:
10.1111/j.1476-5381.2010.00796.x[2] Munoz A, et al. Modulation of bladder afferent signals in normal and spinal cord-injured rats by purinergic P2X3 and P2X2/3receptors. BJU Int. 2012 Oct;110(8 Pt B):E409-414. DOI:
10.1111/j.1464-410X.2012.11189.x